Nicholas explains why compounded semaglutide and tirzepatide were legal, what changed when the shortages ended, the FDA's 2026 crackdown, and questions to ask if you're on a compounded product.
Read the full post: Compounded GLP-1s after the shortage: where things stand in 2026
In this episode
- 00:00 Cold open and intro
- 00:37 Why compounding was allowed
- 00:55 When the shortages ended
- 01:17 What the FDA is policing in 2026
- 01:59 What changed for patients
- 02:06 Questions to ask your provider
- 02:32 Why research GLP-1s are different
- 02:55 Wrap-up and Amino Club code
Peptides covered
Tools and deals
- Free reconstitution and dosing calculator: mypeps.info/calculator
- Amino Club: 40% off with code MYPEPSINFO at aminoclub.com
Sources
- https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- https://cm.healio.com/news/endocrinology/20250221/fda-removes-semaglutide-from-drug-shortage-list
- https://www.pharmaceuticalcommerce.com/view/fda-issues-30-warning-letters-to-telehealth-firms-over-misleading-compounded-glp-1-marketing
- https://www.citizen.org/article/the-miracle-drug-and-the-peptide-craze-breaking-the-fda/
- Full source list in the blog post.
Educational information only, not medical advice. Talk to a licensed clinician before starting, stopping or changing any medication. Research-grade peptides are not FDA-approved drugs.